93.90
-4.07 (-4.15%)
| Previous Close | 97.97 |
| Open | 95.94 |
| Volume | 1,757,674 |
| Avg. Volume (3M) | 2,012,793 |
| Market Cap | 12,316,904,448 |
| Price / Sales | 11.88 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Guardant Health, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 180.00 (Leerink Partners, 91.69%) | Buy |
| Median | 130.00 (38.45%) | |
| Low | 110.00 (Evercore ISI Group, 17.15%) | Hold |
| Average | 133.21 (41.86%) | |
| Total | 13 Buy, 1 Hold | |
| Avg. Price @ Call | 103.24 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 24 Feb 2026 | 130.00 (38.45%) | Buy | 95.40 |
| BTIG | 20 Feb 2026 | 145.00 (54.42%) | Buy | 103.10 |
| 12 Dec 2025 | 140.00 (49.09%) | Buy | 102.07 | |
| Canaccord Genuity | 20 Feb 2026 | 135.00 (43.77%) | Buy | 103.10 |
| 22 Dec 2025 | 125.00 (33.12%) | Buy | 101.34 | |
| Citigroup | 20 Feb 2026 | 150.00 (59.74%) | Buy | 103.10 |
| 11 Dec 2025 | 135.00 (43.77%) | Buy | 101.38 | |
| Evercore ISI Group | 20 Feb 2026 | 110.00 (17.15%) | Hold | 103.10 |
| 05 Jan 2026 | 105.00 (11.82%) | Hold | 101.87 | |
| JP Morgan | 20 Feb 2026 | 130.00 (38.45%) | Buy | 103.10 |
| 15 Dec 2025 | 120.00 (27.80%) | Buy | 102.67 | |
| Leerink Partners | 20 Feb 2026 | 180.00 (91.69%) | Buy | 103.10 |
| 15 Dec 2025 | 155.00 (65.07%) | Buy | 102.67 | |
| Stifel | 20 Feb 2026 | 130.00 (38.45%) | Buy | 103.10 |
| 09 Jan 2026 | 120.00 (27.80%) | Buy | 110.17 | |
| TD Cowen | 20 Feb 2026 | 135.00 (43.77%) | Buy | 103.10 |
| Wells Fargo | 20 Feb 2026 | 125.00 (33.12%) | Buy | 103.10 |
| 15 Dec 2025 | 120.00 (27.80%) | Buy | 102.67 | |
| Baird | 17 Feb 2026 | 120.00 (27.80%) | Buy | 107.11 |
| Guggenheim | 26 Jan 2026 | 135.00 (43.77%) | Buy | 114.74 |
| 05 Jan 2026 | 115.00 (22.47%) | Buy | 101.87 | |
| Mizuho | 17 Dec 2025 | 120.00 (27.80%) | Buy | 97.47 |
| Barclays | 15 Dec 2025 | 120.00 (27.80%) | Buy | 102.67 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |